BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest Down 10.7% in December

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was the target of a significant decrease in short interest in December. As of December 15th, there was short interest totalling 17,290,000 shares, a decrease of 10.7% from the November 30th total of 19,360,000 shares. Based on an average daily volume of 1,990,000 shares, the short-interest ratio is currently 8.7 days.

Institutional Trading of BioCryst Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. Signaturefd LLC raised its position in shares of BioCryst Pharmaceuticals by 560.5% in the second quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 5,599 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in BioCryst Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,322 shares during the period. nVerses Capital LLC acquired a new position in BioCryst Pharmaceuticals in the 2nd quarter worth about $63,000. Quantinno Capital Management LP purchased a new position in BioCryst Pharmaceuticals during the third quarter worth approximately $82,000. Finally, DRW Securities LLC acquired a new stake in BioCryst Pharmaceuticals in the second quarter valued at approximately $74,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on BCRX shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $14.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Finally, Barclays boosted their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $15.60.

BioCryst Pharmaceuticals Trading Down 0.3 %

Shares of NASDAQ BCRX traded down $0.02 during trading on Tuesday, reaching $7.51. 991,457 shares of the company traded hands, compared to its average volume of 2,810,686. BioCryst Pharmaceuticals has a 12-month low of $4.03 and a 12-month high of $8.88. The stock has a market cap of $1.56 billion, a P/E ratio of -12.31 and a beta of 1.79. The firm’s fifty day simple moving average is $7.64 and its 200 day simple moving average is $7.49.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The company had revenue of $117.10 million for the quarter, compared to analysts’ expectations of $113.99 million. During the same quarter in the prior year, the business posted ($0.19) earnings per share. The firm’s revenue was up 35.1% compared to the same quarter last year. As a group, research analysts expect that BioCryst Pharmaceuticals will post -0.38 EPS for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.